July 23, 2014 1:57 AM ET

Biotechnology

Company Overview of Genzyme Corporation

Company Overview

Genzyme Corporation, a biotechnology company, engages in the discovery and development of products and services primarily in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases, and endocrinology worldwide. It offers Cerezyme for treating gaucher disease type I; Fabrazyme for treating fabry disease; Aldurazyme for mucopolysaccharidosis I; Myozyme and Lumizyme for pompe disease; Renagel, a calcium and metal-free phosphate binder that reduces phosphorous levels in chronic kidney disease (CKD) patients who are on dialysis; Renvela for use in dialysis patients and patients with earlier stage CKD; Hectorol, a vitamin D2 treatment for secondary hyperparathyroidism in CK...

500 Kendall Street

Cambridge, MA 02142

United States

Founded in 1981

10,100 Employees

Phone:

617-252-7500

Fax:

617-252-7600

Key Executives for Genzyme Corporation

Chief Executive Officer and President
Age: 59
Chief Financial Officer
Chairman and Chief Executive Officer of Sanofi
Age: 54
Executive Vice President and President of Manufacturing & Corporate Operations
Age: 53
Senior Vice President and President of Personalized Genetic Health
Age: 50
Compensation as of Fiscal Year 2014.

Genzyme Corporation Key Developments

Genzyme and Cleveland Clinic Collaborate to Develop New MS Therapeutics

Genzyme has announced new research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of multiple sclerosis, or MS. This innovative collaboration aligns the research efforts of both organizations around projects which are designed to develop a deep understanding of the pathogenesis and progression of MS and to address the unmet medical needs in MS, particularly progressive forms of the disease. Initially the collaboration will focus on projects that explore strategies to address neurodegeneration, a hallmark of progressive MS, and novel technologies to better understand the pathology of the disease. The collaboration will be led by a joint steering committee comprised of Genzyme and Cleveland Clinic researchers and span a minimum of 5 years.

Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Cleveland Clinic

Genzyme announced the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS. This innovative collaboration aligns the research efforts of both organizations around projects which are designed to develop a deep understanding of the pathogenesis and progression of MS and to address the unmet medical needs in MS, particularly progressive forms of the disease. Initially the collaboration will focus on projects that explore strategies to address neurodegeneration, a hallmark of progressive MS, and novel technologies to better understand the pathology of the disease. The collaboration will be led by a joint steering committee comprised of Genzyme and Cleveland Clinic researchers and span a minimum of 5 years.

Genzyme Announces New Magnetic Resonance Imaging Data from the Lemtrada (Alemtuzumab) Clinical Development Program

Genzyme announced new magnetic resonance imaging (MRI) data from the Lemtrada (alemtuzumab) clinical development program. In Lemtrada patients from the two Phase III clinical trials (both treatment-naïve patients and patients who had active disease on another therapy), MRI effects observed after two years were maintained during the first year of the extension study. Consistent effects were seen across key measures of disease activity (gadolinium (gd)-enhancing, T2 hyperintense and T1 hypointense lesion activity) and effects seen after two years of treatment were sustained at year three. During the third year of follow-up, more than 70% of patients were free of MRI activity indicative of acute inflammation, defined as gd-enhancing or new or enlarging T2 hyperintense lesions. T2 lesion volumes, which reflect the combined burden of permanent brain injury and new lesion formation, increased from year two to three but remained below pre-treatment baseline. The rate of atrophy, as measured by brain parenchymal fraction, already reduced after two years, continued to slow in the third year of follow-up. Approximately 80% of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension. The most common side effects of Lemtrada are infusion associated reactions (headache, rash, pyrexia, nausea, fatigue, urticaria, insomnia, pruritus, diarrhea, chills, dizziness, and flushing), infections (upper respiratory tract and urinary tract), and lymphopenia. Autoimmune conditions (including immune thrombocytopenia, other cytopenias, glomerulonephritis and thyroid disease) and serious infections can occur in patients receiving Lemtrada. A comprehensive risk management program incorporating education and monitoring will support early detection and management of these identified risks. Safety results from the first year of the extension study were previously reported for patients who received Lemtrada in the Phase III CARE-MS studies. No new risks were identified. As previously reported, there were two deaths in the extension study. One was from sepsis and the other was presumed accidental and deemed unrelated to study treatment. The Phase III trials of Lemtrada were randomized, two-year studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a (Rebif(R)) in patients with RRMS who had active disease and were either new to treatment (CARE-MS I) or who had relapsed while on prior therapy (CARE-MS II). In these studies, patients on Lemtrada received two courses of treatment, the first administered via intravenous infusion on five consecutive days, and the second administered on three consecutive days, 12 months later.

Similar Private Companies By Industry

Company Name Region
Nortis Inc. United States
Triton Algae Innovations Ltd. United States
Anadys Pharmaceuticals Inc. United States
Genzyme Corporation United States
Abcam, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
March 10, 2014
Celsior Solution
Private Placement
January 11, 2014
Alnylam Pharmaceuticals, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genzyme Corporation, please visit www.genzyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.